Sponsors

FDA approves Roche’s molecular blood test for malaria

Roche has announced the US Food and Drug Administration (FDA) approval of the cobas Malaria test for use on the cobas 6800/8800 Systems. This approved test can aid healthcare professionals in reducing potential risks of patient infection from transfused blood products. The cobas Malaria test provides a highly sensitive and specific solution to help ensure that infected blood units are removed from the blood supply.

The cobas Malaria molecular test screens whole blood samples for the five main species of Plasmodium parasites that are known to cause human infection. The potential value of a molecular donor screening test for malaria is to improve both blood safety and availability. The test is intended for use in screening blood, organ and tissue donors.

“As the first FDA-approved blood screening test for malaria, this represents an important step forward in safeguarding the global supply of donated blood," said Matt Sause, CEO of Roche Diagnostics. “The approval of cobas Malaria represents a significant advancement in malaria detection, offering healthcare professionals a reliable tool for donor screening and improving the safety of patients worldwide.”

Globally, a large number of possible donors are excluded from giving blood because of travel to or from residences in malaria-endemic areas. Existing microscopy and serological tests are not sensitive enough to reliably mitigate malaria transfusion risk.

The Roche Blood Safety Solutions offering provides the most comprehensive molecular, serological testing and automation options for donor screening in the US market.

The test will be available in the United States at the end of Q2 2024. Approval in CE-marked countries is anticipated later this year.

The cobas Malaria test is a qualitative in vitro nucleic acid screening test, which allows for direct detection of Plasmodium RNA and DNA in whole blood samples from individual human donors. The test, which can be performed with other routine blood donor screening tests, is designed for use on the cobas 6800/8800 Systems.

 

Latest Issues

BSMT 41st Annual Microbiology Conference

Royal Air Force Museum, Hendon, London
21 May, 2026

Clinical and Laboratory Haemostasis 2026

Sheffield Hallam University Atrium Conference Centre, Sheffield S1 1WB
3-4 June, 2026

LabMedUK26

The Eastside Rooms conference centre, Birmingham
8-10 June, 2026

London Biotechnology Show

Excel, London
9-10 June, 2026

Weqas Annual Laboratory Conference 2026

St Andrew’s Stadium, Birmingham
11th June 2026